Neurocrine Biosciences Announces Webcast and Conference Call
Company to Present Positive Results From First Phase III Clinical Trial
With indiplon-IR in 593 Subjects With Transient Insomnia
Company to Present Positive Results From First Phase III Clinical Trial
With indiplon-IR in 593 Subjects With Transient Insomnia
SAN DIEGO, Nov. 14 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will host a Conference Call and Webcast to report on the positive Phase III clinical trial results with indiplon-IR for Transient Insomnia. The Conference Call and Webcast will be held today, Thursday, November 14, 2002 at 9:00AM Eastern Standard Time (EST)/6:00AM Pacific Standard Time (PST). Participants may access the live Conference Call by dialing 1-800-547-8913 (US) or 785-832-2267 (International) and using the access code of NBIX or Neurocrine. The call can also be accessed via the Webcast through the Company's website at www.neurocrine.com or through a link provided by PRNewswire at: http://www.firstcallevents.com/service/ajwz370099355gf12.html
Gary A. Lyons, President and CEO and Paul W. Hawran, Executive Vice President and CFO of Neurocrine Biosciences and members of the senior management team will present the results from the first Phase III clinical trial with indiplon-IR. In addition, members of the medical community specializing in sleep medicine will comment on the significance of these results. If you are unable to attend the Webcast and would like further information on this announcement please contact Claudia Jones or Elizabeth Foster in the Investor Relations Department at Neurocrine Biosciences at (858) 658-7600.
A replay of the call will be available approximately two hours after the call concludes and can be accessed by dialing 1-800-839-3608 (US) or 402-220-2971 (International). The call will be archived until Monday, December 2, 2002.
Neurocrine Biosciences, Inc. is a product-based biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including insomnia, anxiety, depression, malignant brain tumors and peripheral cancers, diabetes, multiple sclerosis, irritable bowel syndrome, eating disorders, pain, stroke, and certain female health disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the Internet at http://www.neurocrine.com .
Make Your Opinion Count - Click Here
http://tbutton.prnewswire.com/prn/11690X76643122
SOURCE Neurocrine Biosciences, Inc.,